BRPI0308365B1 - vacina de dna múltipla para injeção in ovo - Google Patents
vacina de dna múltipla para injeção in ovo Download PDFInfo
- Publication number
- BRPI0308365B1 BRPI0308365B1 BRPI0308365A BR0308365A BRPI0308365B1 BR PI0308365 B1 BRPI0308365 B1 BR PI0308365B1 BR PI0308365 A BRPI0308365 A BR PI0308365A BR 0308365 A BR0308365 A BR 0308365A BR PI0308365 B1 BRPI0308365 B1 BR PI0308365B1
- Authority
- BR
- Brazil
- Prior art keywords
- virus
- dna
- gene
- seq
- avian
- Prior art date
Links
- 238000002347 injection Methods 0.000 title claims abstract description 10
- 239000007924 injection Substances 0.000 title claims abstract description 10
- 229960005486 vaccine Drugs 0.000 title abstract description 44
- 108020004414 DNA Proteins 0.000 claims abstract description 64
- 241000271566 Aves Species 0.000 claims abstract description 47
- 108010041986 DNA Vaccines Proteins 0.000 claims abstract description 47
- 229940021995 DNA vaccine Drugs 0.000 claims abstract description 43
- 102000053602 DNA Human genes 0.000 claims abstract description 15
- 241000700605 Viruses Species 0.000 claims description 75
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 62
- 241000711450 Infectious bronchitis virus Species 0.000 claims description 42
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 239000013612 plasmid Substances 0.000 claims description 22
- 239000013598 vector Substances 0.000 claims description 20
- 241000701047 Gallid alphaherpesvirus 2 Species 0.000 claims description 15
- 241001223089 Tremovirus A Species 0.000 claims description 12
- 241000132980 Turkey adenovirus 3 Species 0.000 claims description 12
- 241000701063 Gallid alphaherpesvirus 1 Species 0.000 claims description 11
- 230000000890 antigenic effect Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 241000700647 Variola virus Species 0.000 claims description 7
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 101150008820 HN gene Proteins 0.000 claims description 3
- 101150093578 VP2 gene Proteins 0.000 claims description 3
- 101150029683 gB gene Proteins 0.000 claims description 3
- 101150082239 G gene Proteins 0.000 claims description 2
- 108010046722 Thrombospondin 1 Proteins 0.000 claims description 2
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000702626 Infectious bursal disease virus Species 0.000 claims 1
- 101150027674 S1 gene Proteins 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 63
- 201000010099 disease Diseases 0.000 abstract description 62
- 235000013601 eggs Nutrition 0.000 abstract description 38
- 239000012634 fragment Substances 0.000 abstract description 26
- 230000003612 virological effect Effects 0.000 abstract description 25
- 238000000034 method Methods 0.000 abstract description 15
- 244000144977 poultry Species 0.000 abstract description 14
- 238000002255 vaccination Methods 0.000 abstract description 12
- 230000028993 immune response Effects 0.000 abstract description 10
- 108700005077 Viral Genes Proteins 0.000 abstract description 9
- 230000001681 protective effect Effects 0.000 abstract description 9
- 108091007433 antigens Proteins 0.000 abstract description 8
- 239000000427 antigen Substances 0.000 abstract description 7
- 102000036639 antigens Human genes 0.000 abstract description 7
- 230000001939 inductive effect Effects 0.000 abstract description 7
- 210000004381 amniotic fluid Anatomy 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 108010067390 Viral Proteins Proteins 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 238000011534 incubation Methods 0.000 abstract 1
- 208000006758 Marek Disease Diseases 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 19
- 229920001184 polypeptide Polymers 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 241000287828 Gallus gallus Species 0.000 description 14
- 235000013330 chicken meat Nutrition 0.000 description 14
- 230000002458 infectious effect Effects 0.000 description 14
- 208000010359 Newcastle Disease Diseases 0.000 description 11
- 230000012447 hatching Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 235000013594 poultry meat Nutrition 0.000 description 11
- 206010006451 bronchitis Diseases 0.000 description 10
- 101710081079 Minor spike protein H Proteins 0.000 description 9
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 9
- 241000713826 Avian leukosis virus Species 0.000 description 8
- 150000007523 nucleic acids Chemical group 0.000 description 8
- 238000001514 detection method Methods 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 239000013615 primer Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 241000272525 Anas platyrhynchos Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 3
- 101710114810 Glycoprotein Proteins 0.000 description 3
- 101710181008 P protein Proteins 0.000 description 3
- 101710177166 Phosphoprotein Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 101710167605 Spike glycoprotein Proteins 0.000 description 3
- 101710198474 Spike protein Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 229940031551 inactivated vaccine Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000713838 Avian myeloblastosis virus Species 0.000 description 2
- 208000010884 Bursa disease Diseases 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710197658 Capsid protein VP1 Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000711504 Paramyxoviridae Species 0.000 description 2
- 102000007982 Phosphoproteins Human genes 0.000 description 2
- 108010089430 Phosphoproteins Proteins 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
- 241000712909 Reticuloendotheliosis virus Species 0.000 description 2
- 101710108545 Viral protein 1 Proteins 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001669 bursa of fabricius Anatomy 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101150062031 L gene Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001559185 Mammalian rubulavirus 5 Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical class CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102100024147 Protein phosphatase 1 regulatory subunit 14A Human genes 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000711931 Rhabdoviridae Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101150024766 VP1 gene Proteins 0.000 description 1
- 101150036700 VP3 gene Proteins 0.000 description 1
- 108091034135 Vault RNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108010065667 Viral Matrix Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 241000701792 avian adenovirus Species 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000012677 causal agent Substances 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 229940016590 sarkosyl Drugs 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36254702P | 2002-03-08 | 2002-03-08 | |
| US10/377,718 US7029681B2 (en) | 2002-03-08 | 2003-03-04 | Multiple and multivalent DNA vaccines in ovo |
| PCT/US2003/006811 WO2003075843A2 (en) | 2002-03-08 | 2003-03-06 | Multiple and multivalent dna vaccines in ovo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR0308365A BR0308365A (pt) | 2005-09-06 |
| BRPI0308365B1 true BRPI0308365B1 (pt) | 2016-12-27 |
Family
ID=27807969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0308365A BRPI0308365B1 (pt) | 2002-03-08 | 2003-03-06 | vacina de dna múltipla para injeção in ovo |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7029681B2 (enExample) |
| EP (1) | EP1490105B1 (enExample) |
| JP (2) | JP4999258B2 (enExample) |
| CN (2) | CN1646157B (enExample) |
| AU (1) | AU2003216531B2 (enExample) |
| BR (1) | BRPI0308365B1 (enExample) |
| CA (1) | CA2478081C (enExample) |
| IL (2) | IL163859A0 (enExample) |
| MX (1) | MXPA04008692A (enExample) |
| WO (1) | WO2003075843A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037506B2 (en) * | 2002-03-08 | 2006-05-02 | Schweltzer Chemical Corporation Ltd. | Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry |
| US8956628B2 (en) * | 2007-12-13 | 2015-02-17 | Zoetis Products Llc | Bacteriophage preparations and method of use thereof |
| BR112014008161A2 (pt) | 2011-10-21 | 2017-04-11 | Intervet Int Bv | vírus da doença de marek não patogênico recombinante, método para a preparação do mesmo, molécula do ácido nucleico, célula hospedeira, vacina para aves domésticas, método para a preparação de uma vacina, uso de um vírus da doença de marek não patogênico recombinante, e, método de vacinação de aves domésticas |
| US8932604B2 (en) | 2011-10-21 | 2015-01-13 | Intervet Inc. | Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens |
| EP2644702A1 (en) * | 2012-03-30 | 2013-10-02 | Ceva Sante Animale | Multivalent recombinant avian herpes virus and vaccine for immunizing avian species |
| CN102895660B (zh) * | 2012-10-25 | 2014-04-23 | 中国兽医药品监察所 | 一种鸭病毒性肝炎二价灭活疫苗 |
| US9950059B2 (en) | 2014-02-25 | 2018-04-24 | The United States Of America, As Represented By The Secretary Of Agriculture. | Immunogenic composition |
| CN110295149B (zh) * | 2019-06-24 | 2022-06-24 | 四川农业大学 | 一种突变株3型鸭甲肝病毒ch-p60-117c株及构建方法 |
| US11299517B2 (en) * | 2020-04-15 | 2022-04-12 | The United States Of America, As Represented By The Secretary Of Agriculture | Recombinant vaccine against Marek's disease and Newcastle disease |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US182241A (en) * | 1876-09-12 | Improvement in animal-traps | ||
| US3575A (en) * | 1844-05-06 | Improvement | ||
| US4458630A (en) | 1982-06-22 | 1984-07-10 | The United States Of America As Represented By The Secretary Of Agriculture | Disease control in avian species by embryonal vaccination |
| EP0434747B1 (en) * | 1988-09-13 | 1999-05-19 | Merial | RECOMBINANT VACCINES BASED ON THE gB-PROTEIN OF MAREK'S DISEASE VIRUS |
| ATE200735T1 (de) | 1989-10-02 | 2001-05-15 | Univ Arkansas | Impfstoffkonjugat |
| US5397568A (en) | 1989-10-02 | 1995-03-14 | Whitfill; Craig E. | Method of treating infectious bursal disease virus infections |
| US5056464A (en) | 1990-01-18 | 1991-10-15 | Embrex, Inc. | Automated injection system for avian embryos with advanced fluid delivery system |
| US5595912A (en) | 1990-05-04 | 1997-01-21 | University Of Maryland College Park | Specific DNA and RNA sequences associated with US IBDV variants, vector carrying DNA sequences, host carrying cloned vector, deduced amino acid sequences, vaccine and method of vaccination |
| ZA924203B (en) | 1991-06-18 | 1993-03-31 | Akzo Nv | Coccidiosis poultry vaccine |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| JPH06141853A (ja) * | 1992-10-30 | 1994-05-24 | Chemo Sero Therapeut Res Inst | 組換え鶏伝染性喉頭気管炎ウイルス及びその製法 |
| WO1994019014A1 (en) * | 1993-02-26 | 1994-09-01 | Syntro Corporation | Recombinant fowlpox virus s-fpv-043 and uses thereof |
| WO1995018860A1 (en) * | 1994-01-11 | 1995-07-13 | Cornell Research Foundation, Inc. | Control of marek's disease by the inhibition of latency and tumor cell development |
| CA2192994A1 (en) | 1994-06-20 | 1995-12-28 | Henry D. Stone | In ovo immunization of avian embryos with oil-emulsion vaccines |
| US5817320A (en) | 1994-06-20 | 1998-10-06 | The United States Of America As Represented By The Secretary Of The Agriculture | In ovo immunization of avian embryos with oil-emulsion vaccines |
| JPH08116976A (ja) * | 1994-10-20 | 1996-05-14 | Chemo Sero Therapeut Res Inst | 免疫用核酸調製物およびこれを用いた免疫方法 |
| EP0837929A2 (en) | 1995-07-07 | 1998-04-29 | Nippon Zeon Co., Ltd. | Marek's disease virus genes and their use in vaccines for protection against marek's disease |
| FR2751225B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
| US5699751A (en) | 1996-10-02 | 1997-12-23 | Embrex, Inc. | Method and apparatus for in ovo injection |
| US6048535A (en) * | 1997-06-12 | 2000-04-11 | Regents Of The University Of Minnesota | Multivalent in ovo avian vaccine |
| JP4091152B2 (ja) * | 1997-09-19 | 2008-05-28 | 財団法人化学及血清療法研究所 | 金コロイドを含む核酸調製物 |
| UY25347A1 (es) | 1998-01-12 | 1999-05-14 | Embrex Inc | Procedimiento de inyeccion multiple para el tratamiento de embriones aviarios in ovo, y aparato automatizado para la inyeccion in ovo. |
| US6286455B1 (en) | 1998-01-12 | 2001-09-11 | Embrex, Inc. | Automated in ovo injection apparatus |
-
2003
- 2003-03-04 US US10/377,718 patent/US7029681B2/en not_active Expired - Lifetime
- 2003-03-06 BR BRPI0308365A patent/BRPI0308365B1/pt not_active IP Right Cessation
- 2003-03-06 CA CA2478081A patent/CA2478081C/en not_active Expired - Fee Related
- 2003-03-06 CN CN038080001A patent/CN1646157B/zh not_active Expired - Fee Related
- 2003-03-06 WO PCT/US2003/006811 patent/WO2003075843A2/en not_active Ceased
- 2003-03-06 MX MXPA04008692A patent/MXPA04008692A/es active IP Right Grant
- 2003-03-06 IL IL16385903A patent/IL163859A0/xx unknown
- 2003-03-06 CN CN200910212389A patent/CN101703770A/zh active Pending
- 2003-03-06 AU AU2003216531A patent/AU2003216531B2/en not_active Ceased
- 2003-03-06 EP EP03744203.5A patent/EP1490105B1/en not_active Expired - Lifetime
- 2003-03-06 JP JP2003574119A patent/JP4999258B2/ja not_active Expired - Fee Related
-
2004
- 2004-09-01 IL IL163859A patent/IL163859A/en not_active IP Right Cessation
-
2009
- 2009-06-17 JP JP2009144188A patent/JP2009203242A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1490105A4 (en) | 2006-04-19 |
| JP2005519943A (ja) | 2005-07-07 |
| US7029681B2 (en) | 2006-04-18 |
| EP1490105B1 (en) | 2013-10-02 |
| IL163859A (en) | 2010-05-17 |
| AU2003216531B2 (en) | 2006-11-30 |
| JP2009203242A (ja) | 2009-09-10 |
| JP4999258B2 (ja) | 2012-08-15 |
| CN1646157A (zh) | 2005-07-27 |
| CA2478081C (en) | 2011-04-19 |
| AU2003216531A1 (en) | 2003-09-22 |
| EP1490105A2 (en) | 2004-12-29 |
| US20030175291A1 (en) | 2003-09-18 |
| MXPA04008692A (es) | 2005-02-24 |
| IL163859A0 (en) | 2005-12-18 |
| WO2003075843A3 (en) | 2004-07-22 |
| WO2003075843A2 (en) | 2003-09-18 |
| CN1646157B (zh) | 2011-03-02 |
| CA2478081A1 (en) | 2003-09-18 |
| BR0308365A (pt) | 2005-09-06 |
| CN101703770A (zh) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | Current situation and future direction of Newcastle disease vaccines | |
| Schultz-Cherry et al. | Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses | |
| ES2291029T3 (es) | Clones infecciosos del virus de la enfermedad de newcastle, vacunas y analisis diagnosticos. | |
| JP6505593B2 (ja) | 多価組換型鳥ヘルペスウイルス及び鳥類を免疫化するためのワクチン | |
| US6764684B2 (en) | Avian herpesvirus-based recombinant infectious bursal disease vaccine | |
| ES2220333T3 (es) | Mutantes del virus de la enfermedad infeccionsa de las bursas (ibdv) adaptados por ingenieria genetica para el cultivo celular. | |
| JP2009203242A (ja) | インビボ（ｉｎｖｉｖｏ）マルチプルｄｎａワクチンと多価ｄｎａワクチン | |
| JP5432703B2 (ja) | 組み換えモノネガウイルス目ウイルスベクター | |
| US20200069788A1 (en) | Avian reovirus vaccines | |
| Ali et al. | A mini-review on Newcastle disease virus in Egypt, with particular references to common vaccines and their development | |
| ES2223392T3 (es) | Un virus recombinante de la enfermedad de newcastle como vacuna embrionaria. | |
| US7037506B2 (en) | Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry | |
| WO2019069720A1 (ja) | 組み換え鳥パラミクソウイルス | |
| JP2002095485A (ja) | 広域スペクトルの伝染性ファブリキウス嚢病ウイルスワクチン | |
| Mosley et al. | Avian viral vector vaccines for infectious bursal disease | |
| BR112021022651B1 (pt) | Proteína spike do coronavírus aviário, partícula viral, coronavírus aviário, composições imunogênicas, método para cultivar coronavírus aviário e ibv (vírus da bronquite infecciosa) | |
| BR122023008707B1 (pt) | Método para a produção ou fabricação de um coronavírus aviário com um tropismo estendido de célula ou tecido | |
| JP2001086983A (ja) | 家禽用ワクチン | |
| BRPI1104835A2 (pt) | Processo para obtenção de virus geneticamente modificado para uso como vacina contra a doença de gumboro e composição farmaceuticas contendo os mesmos | |
| BR112017016181B1 (pt) | Mdv1 recombinante e usos do mesmo | |
| BR112017013595B1 (pt) | Vírus herpes de peru recombinante, método in vitro para preparação de uma vacina, e, vacina para aves |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/12/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 19A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2661 DE 04-01-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |